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Dear Editor 
                          We read with great interest the article by Kjaer et al. [1] aiming at 
investigating the performance of a standardized qPCR assay in quantification of BCR-
ABL1 transcripts in chronic myeloid leukaemia (CML) patients harbouring the e13a2 or 
e14a2 variant of the M-bcr (p210) fusion protein.  
 
  The Authors observed a significant difference in the slopes of qPCR amplification 
curves between the variants, and compared qPCR results with absolute quantitation of 
BCR-ABL1 by droplet digital PCR (ddPCR), demonstrating that mean qPCR values were 
consistently higher for e13a2 patients and lower for e14a2 patients as compared to 
ddPCR, while no significant difference was present considering the absolute 
quantification by ddPCR. Several groups, including ours, showed that e14a2 variant is 
associated to earlier, deeper and more stable molecular response than e13a2 [2-4], 
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large cohort by the European Treatment and Outcome Study group [5]. Based on these 
observations the e14a2 variant has been considered biologically more favourable. The 
data presented by the Authors contrast with this interpretation and attribute the 
phenomenon at least partly to a technical aspect. 
 
We recently studied 142 CML patients with deep molecular response (DMR ≥MR4.0) 
according to qPCR and comparatively monitored them for a median time of 24 months 
by quantitative and digital PCR. In this study, we found that the threshold of 0.468 BCR-
ABL1 copies/μL allowed a better identification of the patients with “stable” DMR and, at 
TKI discontinuation, a better recognition of the patients with a higher probability to 
maintain the treatment-free remission (TFR). On the contrary, patients’ stratification 
according to the standard qPCR classes (i.e. MR4.0, MR4.5, and MR5.0) failed at it [6].  
 We revised our 142 CML patients’ samples in light of the transcript variants. Indeed, a 
difference was appreciable considering all the 512 samples collected throughout the 
duration of the study and evaluating the detectability of BCR-ABL1 by qPCR. e13a2 
samples presented a higher rate (115/205) of detection compared to e14a2 ones 
(144/307) (p=0.0367). No difference was appreciable in terms of dPCR quantification, 
neither for fluorescence intensity, as considered by Kjaer and colleagues, nor for 
absolute level of transcript. (Figure 1).  
 
 Moreover, we confirmed that there were no differences in the mean of BCR-ABL1 
values by dPCR between e13a2 and e14a2 patients at enrollment. Specifically, the 
proportion of patients with e13a2 or e14a2 was 45% and 55%, respectively, among 
patients with ≥0.468 BCR-ABL1 copies/μL, and 35% and 60%, respectively, among 
patients with <0.468 BCR-ABL1 copies/μL (p=0.573). In this last category, 5% 
presented both the transcripts. Therefore, in our cohort dPCR lasts the only variable 
able to identify patients with stable DMR and beneficiaries of TKI discontinuation. 
These findings and the data reported by Kjaer et al. pose an important question about 
the reliability of BCR-ABL1 measurement by qPCR, especially in patients with the e13a2 
variant. How many of them would not have been considered eligible for a treatment 
discontinuation or were incorrectly evaluated as molecularly relapsed? Is the reported 
higher probability of TFR maintenance in e14a2 patients [7,8] due to a technical issue 
rather than a biological phenomenon? 
 
 We totally agree with Kjaer et al. about the limitations of qPCR and strongly support the 
usefulness of dPCR as feasible alternative to provide a robust, sensitive and accurate 
quantitation of BCR-ABL1 in routine clinical practice. We also think that in the era of 
more potent TKI, precision medicine and personalized treatment programs, it is the 
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Figure 1. BCR-ABL1 absolute quantification by dPCR. Samples are divided based on the 
transcript variant. dPCR values are reported as BCR-ABL1 copies/l. 
 
 
 
